Skip to content
Open access

Metabolic dysfunction-associated steatotic liver disease and cardiovascular pathology

Sep 2026 · Perm Medical Journal · 0 citations · 53 references

TL;DR

Raising awareness of MASLD among the general public and at-risk populations, unifying existing guidelines for cardiometabolic diseases, and the development of regional and global strategies to combat MASLD are essential to tackle the cardiometabolic pandemic.

Abstract

The data on the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its phenotypes, the evolution of steatotic liver disease terminology and its association with cardiovascular diseases were summarized. A systematic search for relevant publications in the PubMed database was performed. MASLD has become one of the most prevalent and underappreciated cardiovascular threats. It is closely associated with the development and progression of atherosclerotic cardiovascular diseases, arrhythmias, conduction disorders, hypertension and heart failure. Moreover, MASLD is a crucial part of the cardiohepatorenal continuum. Raising awareness of MASLD among the general public and at-risk populations, unifying existing guidelines for cardiometabolic diseases, and the development of regional and global strategies to combat MASLD are essential to tackle the cardiometabolic pandemic.

Read PDF

Similar papers

Review Open access Sep 2026

Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in prevalence worldwide. Pathogenesis of MASLD has been considerably heterogenous. Increased hepatic de novo lipogenesis, adipose tissue dysfunction, genetic predisposition, epigenetic mechanism, and other related factors have been associate...

Kyung-Soo Kim, S. Lim, Cheol-Young Park · 0 citations
Review Open access Nov 2026

Metabolic Dysfunction-Associated Steatotic Liver Disease: Heterogeneity of Its Pathophysiology and Its Relationship with Type 2 Diabetes Mellitus

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide. People with MASLD can progress to cirrhosis and have an increased risk of developing hepatic decompensation and hepatocellular carcinoma. People with MASLD are also at increased risk of type 2 diabe...

S. Schuth, K. Kantartzis, A. Birkenfeld et al. · 0 citations
Review Open access Oct 2026

Metabolic Dysfunction-Associated Steatotic Liver Disease and Extrahepatic Cancers.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, and its high prevalence underscores the central role of metabolic dysregulation in its pathogenesis. Recent epidemiological studies have shown that MASLD is associated not only with hepatocellular carcino...

Shi-Yu Peng, Zhui Ke, Han Ding et al. · 0 citations
Open access Jul 2026

Prevalence and clinical correlates of metabolic dysfunction-associated steatotic liver disease in heart failure

Abstract Background The nomenclature change from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) better encapsulates the associated metabolic milieu. While MASLD is associated with increased heart failure (HF) risk, characteristics and outcomes of MASLD in patients...

N. Chew, Chandramouli Chanchal, W. Tay et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.